| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Transforming growth factor beta-1 proprotein|Latency-associated peptide|LAP|Transforming growth factor beta-1|TGF-beta-1|TGFB1|TGFB |
| Assay Time | |
| Detection Method | |
| Detection Range | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples |
| Sensitivity | |
| Species | |
| Storage | |
| Target | |
| UniProt # |
Background
human TGF-β1 (Transforming Growth Factor Beta 1) is a molecular target commonly studied in immunology, cardiovascular, and cancer research. Growth factors are signaling proteins that influence proliferation, differentiation, and tissue remodeling through receptor activation.
Biological role and mechanism
The biological role of TGF-β1 is typically understood in terms of its molecular category and interaction network. Depending on the model system, it may participate in cell–cell communication, intracellular signaling, enzymatic processing, or regulation of gene expression programs. Mechanistic interpretation is often strengthened by considering upstream regulators and downstream readouts rather than relying on a single marker.
Expression and abundance of TGF-β1 can vary by tissue, cell type, and physiological state. In many systems, levels are influenced by factors such as developmental stage, immune activation, metabolic status, and cellular stress. Because sample matrix and pre-analytical handling can affect measured concentrations, interpretation is typically strongest when experiments keep collection and processing consistent across groups.
Nomenclature and related terms
TGF-β1 (Transforming Growth Factor Beta 1) may also be referenced as Transforming growth factor beta-1 proprotein, Latency-associated peptide, and LAP in the literature or in databases. When comparing results across studies, confirm that the reported analyte refers to the same molecule, species context, and molecular form (e.g., precursor vs mature protein, or soluble vs membrane-associated forms).
Why it matters in research
- Understanding how TGF-β1 relates to innate and adaptive immune responses, cytokine signaling networks, host–pathogen interactions, and immune cell activation and trafficking in immunology, cardiovascular, and cancer research.
- Interpreting shifts in TGF-β1 levels alongside other pathway components or complementary markers.
- Connecting molecular changes to phenotypes such as inflammation, remodeling, metabolism shifts, or cell-state transitions (context-dependent).
Molecular forms and interpretation
For some targets, isoforms, proteolytic processing, or post-translational modifications (such as phosphorylation or glycosylation) can influence function and apparent abundance. If multiple molecular forms are expected in your model, align interpretation with the form most relevant to the biological question.
Disease and translational relevance
TGF-β1 has been investigated across diverse physiological and disease contexts, and changes in its abundance have been reported in areas aligned with immunology, cardiovascular, and cancer studies. These associations are interpreted as research findings rather than diagnostic or therapeutic claims, and they should be evaluated alongside model-specific covariates and study design.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression
IF: 37.3 Journal: Molecular Cancer Author: Digestive Diseases Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China. Cited Date: 2024-03-15
Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment
IF: 11.3 Journal: Journal of Experimental & Clinical Cancer Research Author: Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy Cited Date: 2023-07-28
Ceria‐Nanoparticle‐Entangled Reticulation for Angiogenic and Therapeutic Embrocation for Multifactorial Approach to Treat Diabetic Wound
IF: 10 Journal: Advanced Healthcare Materials Author: Center for Nanoparticle Research, Institute for Basic Science (IBS), Seoul, 08826, Republic of Korea. Cited Date: 2025-04-11
Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance
IF: 8.756 Journal: Oncogene Cited Date: 2022-12-02
Glyphosate targets FYN to regulate glycolysis and promote glioblastoma proliferation: A network toxicology study
IF: 8.5 Journal: International Journal of Biological Macromolecules Author: Department of Prosthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneratio Cited Date: 2025-10-11
Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes
IF: 7.561 Journal: Frontiers in Immunology Cited Date: 2022-03-18
DcR3 suppresses the NF-κB pathway and the NLRP3 inflammasome activation in gouty inflammation
IF: 7.5 Journal: Chinese Medical Journal Author: Research Center of Hyperuricemia and Gout, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China. Cited Date: 2024-09-27
DOP03 The correlation of regulatory miRNAs with cytokine serum levels and cytokine genes’ polymorphisms
IF: 6.992 Journal: Journal of Crohn's and Colitis Cited Date: 2019-01-25
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
IF: 6.63 Journal: Cancer Immunology, Immunotherapy Cited Date: 2022-09-15